BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

UPDATE: The ESTRO and WCB conference dates have been pushed back as a precaution to travel-related health risks in neighboring European countries. 

World Congress of Brachytherapy 2020 and the European Society for Radiotherapy and Oncology ESTRO 2020, will be held at the Reed Meese Congress Center, Vienna, Austria this year,  April 2-4, 2020July 31st to August 4th.  Together they provide a broad spectrum of lectures, exhibits, and information on the state of radiotherapy treatment.   Pyrexar will be represented in both events by Sennewald Medizintechnik GmbH.  


UCSF-Predicting Benefit from Advanced Radiation Technologies

On March 27th-29th, the Department of Radiation Oncology, University of California San Francisco School of Medicine, will offer a CME Course titled "Predicting Benefit from Advanced Radiation Technologies."  The 3-day event will cover a vast array of radiotherapy topics, including two presentations on hyperthermia's role in radiation oncology.  Pyrexar is supporting this event with a sponsorship.  - UCSF Event Registration Link

German Cancer Congress

The German Cancer Congress (DKK / Deutscher Krebskongress) is the largest and oldest congress covering cancer diagnostics and therapy in German-speaking countries. The 34th annual congress will take place from February 19th - 22nd, 2020, at the CityCube in Berlin. Thermal oncology experts, Dr. Sennewald Medizintechnik, will be exhibiting Pyrexar's hyperthermia system solutions in booth D1.5 in hall B.

If you are planning on attending, please make a note to attend Hyperthermia Interdisciplinary Working Group (IAH) session titled: Hyperthermia - Indications and Combinations, on Saturday, February 22nd, 2020.

CHAIRS: Daniel Zips MD, UMC Tubingen, Germany
Felix Krummradt, UMC Heidelberg, Germany
Peter Wust MD
UMC Charité Berlin
"Current state of technology and relevant studies."
Oliver Ott MD
UMC Erlangen
"Neoadjuvant radiochemotherapy with regional hyperthermia in rectal cancer (HyRec phase II study)"
Cihan Gani MD
UMC Tubingen
"Hyperthermia as part of organ-preserving therapy concepts for rectal cancer."
Rolf Isssels MD
UMC Munich Grosshadern
"Interim analysis of the HEAT phase III study on adjuvant therapy for pancreatic cancer."
Udo Gaipl PhD
UMC Erlangen
"Hyperthermia and immune response."

A complete schedule of events is available on the organization's website.

Pyrexar Medical is a proud sponsor of the Eleventh Biennial Conference of the IAHOM ( Indian Association of Hyperthermic Oncology and Medicine) held in Mumbai on 15th & 16th February 2020. The meeting is co-sponsored by the Society for Cancer Research and Communication and Nanavati Multispeciality Hospital.

Nanavati Hospital Vile Parle Mumbai

Topics at the conference include

    • Immunology relevant to Hyperthermia
    • Nanotechnology
    • Economics of setting up Hyperthermia Center in Emerging Economies
    • Hyperthermia from India HIPEC and HIFU
    • Innovations in Technology

 You may recognize several of the hyperthermia luminaries scheduled to speak which include, Dr. Zeljko Vujaskovic of the University of Maryland Medical Center, Dr. Jacoba van der Zee, Dr. Gerard van Rhoon, and Dr. Hans Creeze of Erasmus MC, The Netherlands, 

Indian association of hyperthermic oncology and medicinenanvati logo .Society of Cancer Research and Communication

A special thanks to Dr. Nagraj G. Hiulgol and Dr. Jugna Bhattacharya for their work in bringing hyperthermia awareness and education to India.

 Link to the conference brochure download.

 

Our friends at Thermosome continue to move their drug targeting platform forward. In a recent video, (shown below) they describe the development of their drug targeting system using focal heat as the release trigger.


BSD-2000 3D/MR makes an appearance at 01:03

Thermosome has developed a drug release system that targets the tumor with a 10 to 15 times higher local drug concentration over standard delivery. They do this by micro-encapsulating approved chemo drugs with a shell of thermosensitive liposomes (TSL). The TSL encapsulated drug is circulated via IV to the patient during the thermal therapy treatment, only releasing it when the surrounding environment reaches 42˚C, which is 5˚C higher than average body temperature.  

thermosome video

Deep Regional Hyperthermia plays an important role by creating the necessary 42˚C microenvironment around the tumor. Combining Thermosome with the BSD-2000 3D/MR provides stable temperatures in a defined focal region.  Additional patient benefit is derived from the positive thermal effects of increased blood flow and perfusion at the tumor site, the immune modulation generated by heating, and the increased concentration of chemotherapeutics.  The visual aspect of the MRI guidance (3D heat zone mapping) offers operator assurance that the tumor area is entirely at the target temperature when the drug is administered. 

Thermosome is actively looking for partners, learn more about at http://www.thermosome.com/